WS #15444
PepsiCo is running out of time to meet turnaround targets set by activist investor Elliott Management, while simultaneously facing a structural threat from GLP-1 weight-loss drugs that are reducing demand for sugary beverages and snacks. The WHO's new guidelines further sidelining GLP-1s for child obesity may offer temporary relief, but the long-term narrative of volume decline in core calorie-dense products remains a significant overhang for the stock.
PepsiCo Elliott and GLP-1 Headwinds
PepsiCo is running out of time to meet turnaround targets set by activist investor Elliott Management, while simultaneously facing a structural threat from GLP-1 weight-loss drugs that are reducing demand for sugary beverages and snacks. The WHO's new guidelines further sidelining GLP-1s for child obesity may offer temporary relief, but the long-term narrative of volume decline in core calorie-dense products remains a significant overhang for the stock.